Litcius/Paper detail

Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients

Myuran Thana, Naveen S. Basappa, Sunita Ghosh, Christian Kollmannsberger, Daniel Y.C. Heng, Aaron R. Hansen, Jeffery Graham, Denis Soulières, M. Neil Reaume, Aly‐Khan A. Lalani, Vincent Castonguay, Georg A. Bjarnason, François Patenaude, Rodney H. Breau, Frédéric Pouliot, Anil Kapoor, Lori Wood

2021Clinical Genitourinary Cancer13 citationsDOI

Topics & Concepts

IpilimumabNivolumabMedicineDiscontinuationRenal cell carcinomaInternal medicineCohortOncologyKidney cancerAdverse effectExpanded accessCancerSurgeryImmunotherapyRenal cell carcinoma treatmentFerroptosis and cancer prognosisCancer Immunotherapy and Biomarkers
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients | Litcius